探讨影响锂剂量和血浆水平的临床因素以及品牌的影响。

IF 3.4 3区 医学 Q2 PHARMACOLOGY & PHARMACY
Therapeutic Advances in Psychopharmacology Pub Date : 2024-10-15 eCollection Date: 2024-01-01 DOI:10.1177/20451253241285883
Carol Paton, Paul Bassett, Olivia Rendora, Thomas R E Barnes
{"title":"探讨影响锂剂量和血浆水平的临床因素以及品牌的影响。","authors":"Carol Paton, Paul Bassett, Olivia Rendora, Thomas R E Barnes","doi":"10.1177/20451253241285883","DOIUrl":null,"url":null,"abstract":"<p><strong>Background: </strong>Optimal use of lithium involves adjustment of the dose, to keep the plasma level within the narrow, recommended range. Brand-specific prescribing has long been considered critical to achieving this aim, but this is a convention based on very limited data.</p><p><strong>Objectives: </strong>To explore the effect of selected demographic and clinical factors on the relationship between lithium dose and plasma level and determine whether there is an independent effect of lithium brand.</p><p><strong>Design: </strong>Analysis of clinical audit data collected in 2023 as part of a quality improvement programme addressing the use of lithium, conducted by the Prescribing Observatory for Mental Health.</p><p><strong>Methods: </strong>Data were collected from clinical records using a bespoke proforma, submitted online and analysed using SPSS.</p><p><strong>Results: </strong>Data were submitted for 4405 patients who had been prescribed solid-dosage formulations of lithium for more than a year. Priadel<sup>®</sup> was prescribed for 3722 (84%) of these patients, Camcolit<sup>®</sup> for 112 (2.5%) and the prescription was written generically for 554 (12.5%). Compared with Priadel, where Camcolit was prescribed, the mean daily dose was 10% higher and the mean plasma lithium level was 11% higher. A multivariable analysis was conducted to explore the relationship between selected clinical variables and maintenance lithium dose. This found that in 4213 patients whose most recent plasma lithium level was between 0.3 and 1.19 mmol/L, the variables age, sex, ethnicity, psychiatric diagnosis and the severity of chronic kidney disease were independently associated with dose while the brand of lithium prescribed was not.</p><p><strong>Conclusion: </strong>Our findings replicate those of previous studies with respect to the demographic and clinical variables that can be expected to influence lithium dosage in routine clinical practice. This reinforces the need to titrate the dosage for each individual patient, to achieve and maintain the target plasma level. However, the findings suggest that the Priadel and Camcolit brands of lithium are essentially interchangeable.</p>","PeriodicalId":23127,"journal":{"name":"Therapeutic Advances in Psychopharmacology","volume":null,"pages":null},"PeriodicalIF":3.4000,"publicationDate":"2024-10-15","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11481060/pdf/","citationCount":"0","resultStr":"{\"title\":\"Exploring the clinical factors affecting lithium dose and plasma level and the effect of brand.\",\"authors\":\"Carol Paton, Paul Bassett, Olivia Rendora, Thomas R E Barnes\",\"doi\":\"10.1177/20451253241285883\",\"DOIUrl\":null,\"url\":null,\"abstract\":\"<p><strong>Background: </strong>Optimal use of lithium involves adjustment of the dose, to keep the plasma level within the narrow, recommended range. Brand-specific prescribing has long been considered critical to achieving this aim, but this is a convention based on very limited data.</p><p><strong>Objectives: </strong>To explore the effect of selected demographic and clinical factors on the relationship between lithium dose and plasma level and determine whether there is an independent effect of lithium brand.</p><p><strong>Design: </strong>Analysis of clinical audit data collected in 2023 as part of a quality improvement programme addressing the use of lithium, conducted by the Prescribing Observatory for Mental Health.</p><p><strong>Methods: </strong>Data were collected from clinical records using a bespoke proforma, submitted online and analysed using SPSS.</p><p><strong>Results: </strong>Data were submitted for 4405 patients who had been prescribed solid-dosage formulations of lithium for more than a year. Priadel<sup>®</sup> was prescribed for 3722 (84%) of these patients, Camcolit<sup>®</sup> for 112 (2.5%) and the prescription was written generically for 554 (12.5%). Compared with Priadel, where Camcolit was prescribed, the mean daily dose was 10% higher and the mean plasma lithium level was 11% higher. A multivariable analysis was conducted to explore the relationship between selected clinical variables and maintenance lithium dose. This found that in 4213 patients whose most recent plasma lithium level was between 0.3 and 1.19 mmol/L, the variables age, sex, ethnicity, psychiatric diagnosis and the severity of chronic kidney disease were independently associated with dose while the brand of lithium prescribed was not.</p><p><strong>Conclusion: </strong>Our findings replicate those of previous studies with respect to the demographic and clinical variables that can be expected to influence lithium dosage in routine clinical practice. This reinforces the need to titrate the dosage for each individual patient, to achieve and maintain the target plasma level. However, the findings suggest that the Priadel and Camcolit brands of lithium are essentially interchangeable.</p>\",\"PeriodicalId\":23127,\"journal\":{\"name\":\"Therapeutic Advances in Psychopharmacology\",\"volume\":null,\"pages\":null},\"PeriodicalIF\":3.4000,\"publicationDate\":\"2024-10-15\",\"publicationTypes\":\"Journal Article\",\"fieldsOfStudy\":null,\"isOpenAccess\":false,\"openAccessPdf\":\"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11481060/pdf/\",\"citationCount\":\"0\",\"resultStr\":null,\"platform\":\"Semanticscholar\",\"paperid\":null,\"PeriodicalName\":\"Therapeutic Advances in Psychopharmacology\",\"FirstCategoryId\":\"3\",\"ListUrlMain\":\"https://doi.org/10.1177/20451253241285883\",\"RegionNum\":3,\"RegionCategory\":\"医学\",\"ArticlePicture\":[],\"TitleCN\":null,\"AbstractTextCN\":null,\"PMCID\":null,\"EPubDate\":\"2024/1/1 0:00:00\",\"PubModel\":\"eCollection\",\"JCR\":\"Q2\",\"JCRName\":\"PHARMACOLOGY & PHARMACY\",\"Score\":null,\"Total\":0}","platform":"Semanticscholar","paperid":null,"PeriodicalName":"Therapeutic Advances in Psychopharmacology","FirstCategoryId":"3","ListUrlMain":"https://doi.org/10.1177/20451253241285883","RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"2024/1/1 0:00:00","PubModel":"eCollection","JCR":"Q2","JCRName":"PHARMACOLOGY & PHARMACY","Score":null,"Total":0}
引用次数: 0

摘要

背景:锂的最佳使用包括调整剂量,使血浆水平保持在推荐的狭窄范围内。长期以来,针对特定品牌的处方一直被认为是实现这一目标的关键,但这只是一种基于非常有限数据的惯例:目的:探讨选定的人口统计学和临床因素对锂剂量和血浆水平之间关系的影响,并确定锂品牌是否有独立影响:设计:分析2023年收集的临床审计数据,这是精神卫生处方观察站针对锂的使用开展的质量改进计划的一部分:方法:使用定制表格从临床记录中收集数据,在线提交并使用 SPSS 进行分析:结果:共提交了 4405 名患者的数据,这些患者服用锂固体制剂超过一年。其中,3722 名患者(84%)使用 Priadel®,112 名患者(2.5%)使用 Camcolit®,554 名患者(12.5%)使用通用处方。与开具Camcolit处方的Priadel相比,平均每日剂量高出10%,平均血浆锂含量高出11%。我们进行了一项多变量分析,以探讨选定临床变量与锂维持剂量之间的关系。结果发现,在 4213 名最近血浆锂水平介于 0.3 至 1.19 mmol/L 之间的患者中,年龄、性别、种族、精神病诊断和慢性肾病严重程度等变量与剂量独立相关,而处方的锂品牌则不相关:我们的研究结果与之前的研究结果相同,即在常规临床实践中,人口统计学和临床变量可能会影响锂的剂量。这进一步说明,需要根据每位患者的具体情况调整剂量,以达到并维持目标血浆水平。不过,研究结果表明,Priadel 和 Camcolit 品牌的锂基本上可以互换。
本文章由计算机程序翻译,如有差异,请以英文原文为准。
Exploring the clinical factors affecting lithium dose and plasma level and the effect of brand.

Background: Optimal use of lithium involves adjustment of the dose, to keep the plasma level within the narrow, recommended range. Brand-specific prescribing has long been considered critical to achieving this aim, but this is a convention based on very limited data.

Objectives: To explore the effect of selected demographic and clinical factors on the relationship between lithium dose and plasma level and determine whether there is an independent effect of lithium brand.

Design: Analysis of clinical audit data collected in 2023 as part of a quality improvement programme addressing the use of lithium, conducted by the Prescribing Observatory for Mental Health.

Methods: Data were collected from clinical records using a bespoke proforma, submitted online and analysed using SPSS.

Results: Data were submitted for 4405 patients who had been prescribed solid-dosage formulations of lithium for more than a year. Priadel® was prescribed for 3722 (84%) of these patients, Camcolit® for 112 (2.5%) and the prescription was written generically for 554 (12.5%). Compared with Priadel, where Camcolit was prescribed, the mean daily dose was 10% higher and the mean plasma lithium level was 11% higher. A multivariable analysis was conducted to explore the relationship between selected clinical variables and maintenance lithium dose. This found that in 4213 patients whose most recent plasma lithium level was between 0.3 and 1.19 mmol/L, the variables age, sex, ethnicity, psychiatric diagnosis and the severity of chronic kidney disease were independently associated with dose while the brand of lithium prescribed was not.

Conclusion: Our findings replicate those of previous studies with respect to the demographic and clinical variables that can be expected to influence lithium dosage in routine clinical practice. This reinforces the need to titrate the dosage for each individual patient, to achieve and maintain the target plasma level. However, the findings suggest that the Priadel and Camcolit brands of lithium are essentially interchangeable.

求助全文
通过发布文献求助,成功后即可免费获取论文全文。 去求助
来源期刊
CiteScore
7.90
自引率
2.40%
发文量
35
审稿时长
10 weeks
期刊介绍: Therapeutic Advances in Psychopharmacology delivers the highest quality peer-reviewed articles, reviews, and scholarly comment on pioneering efforts and innovative studies across all areas of psychopharmacology. The journal has a strong clinical and pharmacological focus and is aimed at clinicians and researchers in psychopharmacology, providing a forum in print and online for publishing the highest quality articles in this area.
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
确定
请完成安全验证×
copy
已复制链接
快去分享给好友吧!
我知道了
右上角分享
点击右上角分享
0
联系我们:info@booksci.cn Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。 Copyright © 2023 布克学术 All rights reserved.
京ICP备2023020795号-1
ghs 京公网安备 11010802042870号
Book学术文献互助
Book学术文献互助群
群 号:481959085
Book学术官方微信